Lithium Treatment Moderate-Dose Use Study (LiTMUS) for Bipolar Disorder: A Randomized Comparative Effectiveness Trial of Optimized Personalized Treatment With and Without Lithium

Dr. Nierenberg has received consulting fees, advisory board fees, research support, or speakers honoraria from American Drug Utilization Review, American Professional Society of ADHD and Related Disorders, American Psychiatric Association, American Society for Clinical Psychopharmacology, Appliance Computing (Mindsite), AstraZeneca, Basliea, Baystate Medical Center, Belvoir Publishing, Brain Cells, Brandeis University, Bristol-Myers Squibb, Columbia University, Corcept, Dainippon Sumitomo, Eli Lilly, EpiQ, Forest Pharmaceuticals, Hillside Hospital, IMEDEX, International Society for Bipolar Disorders, Johnson & Johnson, MJ Consulting, Medscape, MBL Publishing, New York State, NIMH, Novartis, PamLabs, Pfizer, PGx Health, Physicians Postgraduate Press, Ridge Diagnostics, Schering-Plough, SciMed, Shire, SUNY Buffalo, Takeda/Lundbeck, Targacept, Teva Pharmaceuticals, University of Texas Southwestern Dallas, University of Wisconsin, and University of Pisa; has consulted through the MGH Clinical Trials Network and Institute for Brain Cells, Dianippon Sumitomo/Sepracor, Johnson & Johnson, Labopharm, Merck, Methylation Science, Novartis, PGx Health, Schering-Plough, Shire, Targacept, and Takeda/Lundbeck Pharmaceuticals; and owns stock options in Appliance Computing and Brain Cells. Through Massachusetts General Hospital, Dr. Nierenberg is named for copyrights to the Clinical Positive Affect Scale and the MGH Structured Clinical Interview for the Montgomery-Åsberg Depression Scale exclusively licensed to the MGH Clinical Trials Network and Institute. Dr. Nierenberg is a presenter for the Massachusetts General Hospital Psychiatry Academy (MGHPA). The education programs conducted by the MGHPA were supported through Independent Medical Education grants from Astra Zeneca, Bristol-Myers Squibb, Eli Lilly, and Janssen Pharmaceuticals. Dr. Friedman has received consulting fees, advisory board fees, research support, royalties, or speakers honoraria from Aspect Medical Systems, AstraZeneca, Bristol-Myers Squibb, Cyberonics, Indevus, Medtronics, the NIMH Agency for Healthcare Research and Quality, NorthStar/St. Jude Medical, Novartis, Respironics, Sanofi-Aventis, Springer, and Wyeth-Ayerst. Dr. Bowden has received consulting fees, advisory board fees, research support, or speakers honoraria from Bristol-Myers Squibb, Johnson & Johnson, Merck Pfizer, NIMH, Repligen, and Sanofi-Aventis. Dr. Sylvia has received consulting fees from Bracket Global and Clintara, was a shareholder for Concordant Rater Systems, has received royalties from New Harbinger Publisher, and has presented for the MGHPA. Dr. Thase has received consulting fees, advisory board fees, research support, or speakers honoraria from AstraZeneca, Bristol-Myers Squibb, Dey Pharma, Eli Lilly, Forest Pharmaceuticals, Gerson Lehman Group, GlaxoSmithKline, Guidepoint Global, H. Lundbeck A/S, MedAvante, Merck, Neuronetics, the NIMH Agency for Healthcare Research Quality, Novartis, Ortho-McNeil Pharmaceuticals, Otsuka, PamLab, Pfizer, Schering-Plough, Sepracor, Shire, Supernus Pharmaceuticals, Takeda (Lundbeck), and Transcept Pharmaceuticals; has equity holdings in MedAvante; and has received royalty income from American Psychiatric Foundation, Guilford Publications, Herald House, Oxford University Press, and W.W. Norton. Dr. Thase’s spouse is employed by Embryon (formerly Advogent). Dr. Ketter has received consulting fees, advisory board fees, research support, royalties, or speakers honoraria from American Psychiatric Publishing, AstraZeneca, Astellas Pharmaceuticals, Bristol-Myers Squibb, Cephalon, Eli Lilly, Forest Pharmaceuticals, GlaxoSmithKline, Janssen Pharmaceutica, Merck, the NIMH Agency for Healthcare Research and Quality, Noven Pharmaceuticals, Pfizer, Sunovion, and XenoPort. Dr. Ketter’s spouse is an employee with and holds stock in Johnson & Johnson. Dr. Ostacher has served as a consultant to Sunovion. Dr. Leon has served on independent data and safety monitoring boards for AstraZeneca, Pfizer, and Sunovion; has received consulting fees from the Food and Drug Administration, MedAvante, NIMH, and Roche; and held equity in MedAvante. Dr. Reilly-Harrington has received royalties from the American Psychological Association and Oxford University Press, was a shareholder in Concordant Rater Systems, and has received consulting fees from Bracket Global. Dr. Iosifescu has received consulting or advisory board fees from Aspect Medical, Forest Pharmaceuticals, Ortho-McNeil, and Reed Medical (sponsor of the Massachusetts General Hospital Psychiatry Academy). Dr. Pencina consults for Pamlab and RCT Logic. Ms. Severe is a former employee of NIMH. Dr. Calabrese has received consulting fees, advisory board fees, research support, or speakers honoraria from Abbott, AstraZeneca, Bristol-Myers Squibb, Cephalon, Cleveland Foundation, Dainippon Sumitomo, Eli Lilly, EPI-Q, Forest Pharmaceuticals, France Foundation, GlaxoSmithKline, Health Resources Services Administration, Janssen, Johnson & Johnson, Lundbeck, Merck, NARSAD, Neurosearch, NIMH, Ortho-McNeil, Otsuka, Pfizer, Repligen, Schering-Plough, Servier, Solvay, Stanley Medical Research Institute, Supernus, Synosia, Takeda, the US Department of Defense, and Wyeth, and has provided CME lectures supported by AstraZeneca, Bristol-Myers Squibb, France Foundation, GlaxoSmithKline, Janssen, Johnson & Johnson, Merck, Pfizer, Sanofi-Aventis, Schering-Plough, Solvay, and Wyeth.Funded by NIMH contract NO1MH80001.